Q3 2023 EPS Estimates for Vaxcyte, Inc. (NASDAQ:PCVX) Reduced by Analyst

Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) – Leerink Partnrs cut their Q3 2023 EPS estimates for Vaxcyte in a research report issued on Sunday, August 13th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn ($0.73) per share for the quarter, down from their previous estimate of ($0.70). The consensus estimate for […]

Related Keywords

Leerink Partnrs ,Capital Research Global Investors ,Groupa Streptococcus ,Vanguard Group Inc ,Vaxcyte Company Profile ,Blackrock Inc ,Vaxcyte Inc ,Nasdaq ,Needham Company ,Free Report ,Get Free Report ,Research Global Investors ,Vaxcyte Daily ,Vaxcyte ,Nasdaq Pcvx ,Pcvx ,Medical ,Earnings Estimates ,